Forty percent of respondents had skipped a medical test or treatment to save on costs, and 32% had skipped filling a prescription (or took less medication than prescribed) because of costs.
NORC at the University of Chicago, together with the West Health Institute, released the results of a survey of American adults concerning their attitudes toward healthcare. They found that “healthcare costs have a significant and enduring impact on financial health.”
The survey was conducted among 1302 adults—providing a sample coverage of approximately 97% of US households—between February 15 and February 19 of this year using the AmeriSpeak Panel.
In the past year:
Other Americans reported going without care in order to save money, 40% of respondents had skipped a medical test or treatment to save on costs, and 32% had skipped filling a prescription (or took less medication than prescribed) because of costs.
Among those who had skipped a test or treatment, 60% said that they were afraid of the cost of a serious illness, while only 47% said that they were afraid of getting a serious illness itself. According to the report’s authors, these fears about the cost of treatment are often based on experience; more respondents who had negative financial impacts from previous healthcare costs (56%) feared paying for care than those who had not had previous experiences with financial hardship from healthcare costs (23%).
“It’s shocking and unacceptable that medical bills strike more fear in the hearts of Americans than serious illness,” said Shelley Lyford, president and CEO of West Health Institute, in a statement. “Americans are paying more for healthcare than they should and getting less than they deserve. Bold action is required to lower the sky-high cost of healthcare. The very health and wealth of our nation and its people are at stake.”
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.